4Thomas ED, Buckner CD, Clift RA, et al. Marrow transplantation for acute nonlymphoblastic in leukemia first remission. N Engl J Med 1979;301 ( 11 ) :597-599
5Santos GW , Tutschka PJ ,Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment of busulfan and cyclophophamide. New Engl J Med 1983; 309(22): 1347-1353
6Alyea EE Haesook T, Soiffer RJ, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005;105(4): 1810-1814
7Couriel DR, Saliba RM, Giralt S, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004; 10(3): 178-185
8De Lima M,Anagnostopoulos A, Munsell M,et al. Nonablative versus reduced- intensity conditioning regimens in the treatment of acute myeloid leukemia and high -risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104(3): 865-872
9Champlin R , Khouri I , Shimoni A , et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic hematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111 (1): 18-29
10Huang CA, Fuchimoto Y. Stable chimerism and tolerance a nomyeloablative preparative regimen in a large2animal model. J Clin Inves 2000;105(2):173-181
